December 2018 - First Report Managed Care

Volume
15
Issue 12
December 2018

DEPARTMENTS

Researchers shared estimates of the long-term cost-effectiveness of the PCSK9 inhibitor Praluent (alirocumab) in patients after an acute coronary syndrome (ACS) who had elevated low-density lipoprotein (LDL) cholesterol levels, despite use of high-intensity statins. The findings were presented at the Scientific Sessions 2018 in Chicago, Illinois. | Read More
Citation: